Plunkett Research Online: BeyondSpring

BEYONDSPRING (BYSI:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

BeyondSpring Inc is engaged in clinical stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. The Company has created Plinabulin which is marine derived small-molecule with a number of distinct biological activities.....



BeyondSpring
Ticker: BYSI
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 646 305-6387
Fax: 646 882-4228
Address: 28 Liberty Street
39th Floor
New York, NY 10005 United States

Types Of Business
Industry Ranks

Industry NAICS code:

Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing
ContactsDescription
Lan HuangCEO/Chairman of the Board/Co-Founder/Director
Edward LiuCFO
See More
BeyondSpring Inc is engaged in clinical stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. The Company has created Plinabulin which is marine derived small-molecule with a number of distinct biological activities.....See More See More

Auditor: Ernst & Young Hua Ming LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2017201620152014
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: